RecruitingNCT07539766

OBESE-HFpEF: Towards Preventing Obesity Related HFpEF

OBESE-HFpEF: Prevalence and Mediators of Heart Failure (Preserved Ejection Fraction) in the Dutch Obesity Clinic South - Towards Preventing Obesity Related HFpEF''


Sponsor

Zuyderland Medisch Centrum

Enrollment

250 participants

Start Date

Jan 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Obesity, severe overweight, is a growing problem worldwide and increases the risk of heart failure, especially a type called heart failure with preserved ejection fraction (HFpEF). In HFpEF, the heart becomes stiffer. This makes it harder for the heart to fill with blood, which can lead to shortness of breath during physical activity. In the Netherlands, 15% of the population has obesity. In South Limburg, this is even higher at 19%. Among people with HFpEF, obesity is much more common: about 50% of these patients have obesity. Life expectancy in people with HFpEF is poor, and current treatment mainly focuses on reducing symptoms. Early recognition and treatment of risk factors, such as obesity, are therefore very important. This study includes about 250 people with obesity. Using a heart ultrasound and tests of blood and fat tissue, we will look for early signs of HFpEF and study the effects of weight loss. The measurements will be repeated after 1 and 2 years. The goal of this study is to better understand how obesity contributes to HFpEF and how weight loss affects the heart. This research may help improve future treatments for patients with HFpEF.


Eligibility

Min Age: 35 Years

Inclusion Criteria2

  • Age ≥ 35 years
  • Eligible for surgical treatment for obesity, according to the Dutch guideline, i.e. a BMI ≥ 40 kg/m2 or a BMI ≥ 35 kg/m2 with one or more comorbidities associated with obesity. (23)

Exclusion Criteria7

  • Inability to provide informed consent.
  • A BMI >60 kg/m2
  • Inability of undergoing metabolic bariatric surgery safely.
  • Inability to undergo the study measurement/tests.
  • Not proficient in the Dutch language
  • A medical history of a reduced LVEF at any time, history of severe cardiac valve defects or severe congenital cardiac defects.
  • A medical history of previous metabolic bariatric surgery.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Zuyderland Medisch Centrum Heerlen

Heerlen, Limburg, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07539766


Related Trials